<span item_type="fundamental" item_id="94b1120da3b18262c5bd05af4b4e29e9" counter_id="ST/US/BTSGU" env="prod"></span><span item_type="announcement" item_id="576622253438080769" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 3.334 B.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.17.</p><p>EBIT: As of FY2025 Q3, the actual value is USD 87.84 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Total Revenue</strong>: $3,334 million for Q3 2025, up 28.2% from $2,601 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000119312525253503/btsg-ex99_1.htm"></span></li><li><strong>Pharmacy Solutions Revenue</strong>: $2,967 million for Q3 2025, up 31% from $2,266 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000119312525253503/btsg-ex99_1.htm"></span></li><li><strong>Provider Services Revenue</strong>: $367 million for Q3 2025, up 9% from $336 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000119312525253503/btsg-ex99_1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Gross Profit</strong>: $392 million for Q3 2025, up 21.3% from $323 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000119312525253503/btsg-ex99_1.htm"></span></li><li><strong>Net Income</strong>: $37.5 million for Q3 2025, compared to a net loss of $25.7 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000119312525253503/btsg-ex99_1.htm"></span></li><li><strong>Adjusted EBITDA</strong>: $160 million for Q3 2025, up 37.2% from $117 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000119312525253503/btsg-ex99_1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Provided by Operating Activities</strong>: $107.9 million for Q3 2025, compared to $27.2 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000119312525253503/btsg-ex99_1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Leverage</strong>: 3.31x as calculated under the First Lien Credit Agreement at September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000119312525253503/btsg-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>BrightSpring Health Services increased its 2025 Revenue guidance to $12,500 million to $12,800 million, representing 24.1% to 27.1% growth, and reiterated Adjusted EBITDA guidance of $605 million to $615 million, representing 31.5% to 33.7% growth.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000119312525253503/btsg-ex99_1.htm"></span></li></ul>

BrightSpring Health Services - Unit | 8-K: FY2025 Q3 Revenue: USD 3.334 B